CHEK1 and neoplasm: Furthermore, these findings support the concept that tumours with heightened genomic instability coupled with replicative stress will display enhanced sensitivity towards CHK1 inhibitors, both as single agents and in combination with DNA damaging agents or other DDR inhibitors.